COVID-19 Vaccine Manufacturers Are Not Enthusiastic About Using Defense Production Act
Pfizer and Moderna execs note they have sufficient resources with their partners to meet their vaccine production commitments. J&J, which has a manufacturing arrangement with Sanofi, is ready to ship four million doses of its vaccine upon receiving authorization from FDA.
You may also be interested in...
US is keeping a ‘small inventory’ of AstraZeneca’s vaccine so people in the US can receive it immediately following authorization, White House official says. President Biden seeks to boost vaccine manufacturing in India in parntership with India, Japan, and Australia.
US FDA’s Peter Marks notes timeframe for sponsors to seek licensure at press call announcing emergency use authorization of J&J’s vaccine; Acting Commissioner Woodcock says effectiveness comparisons cannot be made between the three authorized vaccines since they have not been tested head-to-head.
Modified vaccines targeted at new SARS-CoV-2 variants must generate immune response rates not more than 10% below those of the original vaccine, agency says in one of a suite of guidances on medical product development to address variants.